All GSK articles – Page 2
-
Opinion(+)-Pleuromutilin
Total synthesis is sometimes the only way to explore the chemical space around a natural product
-
BusinessAmplifying intelligent drug design
This year’s Chemistry World Entrepreneur of the year is Andrew Hopkins of start-up Exscientia and the University of Dundee, UK
-
BusinessHow do chemical firms last hundreds of years?
What distinguishes companies that thrive from others that failed?
-
ResearchDrug binding simulations promise to get personal
Fast, reliable new molecular dynamic simulation methods set to speed up research are under investigation by GSK
-
NewsPharma giants commit to tackling antimicrobial resistance
Plan to tackle superbugs includes changes to manufacturing and sales incentives
-
BusinessUnpicking doctor payments
Accepting even small meals from drug industry reps appears to influence doctors’ prescription rates
-
OpinionHealing the world
Will GSK’s move towards licensing patents in developing countries, rather than rigidly defending them, improve access to medicines?
-
Business
GSK fined for stalling antidepressant generics
UK Competition and Markets Authority deems pay-for-delay deal illegal and imposes £45m in fines
-
BusinessGSK scientists indicted for trade secret theft
Two researchers accused of passing research data and manufacturing details to Chinese firm
-
BusinessFixing the broken antibiotics business model
With rising resistance and doomsday warnings, focus is turning to alternative economic models to boost antibiotic R&D
-
Business
GSK’s ViiV to buy HIV drugs from BMS
Deal hands over Bristol-Myers Squibb’s entire HIV pipeline as the company looks to quit virology research
-
-
NewsMalaria vaccine pilot studies recommended by WHO
GlaxoSmithKline’s RTS,S vaccine must undergo further testing before being rolled out, says World Health Organization panel
-
BusinessMerger fever sweeps pharma
The life sciences sector has been gripped by a mergers and acquisition frenzy, and it looks set to continue. But what does it mean for the industry?
-
Business
Novartis to buy experimental MS drug from GSK in $1bn deal
Deal will help to bolster Novartis’s pipeline for neurological disorder treatments
-
NewsMalaria vaccine approval first marred by efficacy question mark
Low protection rates in trials and uncertainty over cost-effectiveness leave vaccine’s future up in the air
-
Business
GSK commits to HIV research
Firm will partner with US university and cancels plan to sell its share of ViiV Healthcare joint venture
-
Business
Mergers and moves trigger pharma layoffs
Shire expects to sack 500 or more employees, while Merck and GSK also wield the axe
-
News
Ebola vaccine shown to be safe in humans
GlaxoSmithKline vaccine will now be trialled in Liberia
-
